Relief Therapeutics/NeuroRx's Aviptadil Promise In COVID-19-Associated Respiratory Failure
Randomized Trial Results Expected Later This Quarter
Executive Summary
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Pipeline Watch: Phase III Starts In Hypertension, Atopic Dermatitis
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements
ConserV Bioscience: Getting Ahead Of New COVID-19 Strains
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
Need a specific report? 1000+ reports available
Buy Reports